Literature DB >> 15980331

Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.

Alexander A Firsov1, Irene Y Lubenko, Sergey N Vostrov, Yury A Portnoy, Stephen H Zinner.   

Abstract

Prediction of the relative efficacies of different fluoroquinolones is often based on the ratios of the clinically achievable area under the concentration-time curve (AUC) to the MIC, usually with incorporation of the MIC50 or the MIC90 and with the assumption of antibiotic-independent patterns of the AUC/MIC-response relationships. To ascertain whether this assumption is correct, the pharmacodynamics of seven pharmacokinetically different quinolones against two clinical isolates of Staphylococcus aureus were studied by using an in vitro model. Two differentially susceptible clinical isolates of S. aureus were exposed to two 12-h doses of ciprofloxacin (CIP) and one dose of gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), levofloxacin (LVX), moxifloxacin (MXF), and trovafloxacin (TVA) over similar AUC/MIC ranges from 58 to 932 h. A specific bacterial strain-independent AUC/MIC relationship with the antimicrobial effect (I(E)) was associated with each quinolone. Based on the I(E)-log AUC/MIC relationships, breakpoints (BPs) that are equivalent to a CIP AUC/MIC ratio of 125 h were predicted for GRX, MXF, and TVA (75 to 78 h), GAT and GEM (95 to 103 h) and LVX (115 h). With GRX and LVX, the predicted BPs were close to those established in clinical settings (no clinical data on other quinolones are available in the literature). To determine if the predicted AUC/MIC BPs are achievable at clinical doses, i.e., at the therapeutic AUCs (AUC(ther)s), the AUC(ther)/MIC50 ratios were studied. These ratios exceeded the BPs for GAT, GEM, GRX, MXF, TVA, and LVX (750 mg) but not for CIP and LVX (500 mg). AUC/MIC ratios above the BPs can be considered of therapeutic potential for the quinolones. The highest ratios of AUC(ther)/MIC50 to BP were achieved with TVA, MXF, and GEM (2.5 to 3.0); intermediate ratios (1.5 to 1.6) were achieved with GAT and GRX; and minimal ratios (0.3 to 1.2) were achieved with CIP and LVX.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980331      PMCID: PMC1168651          DOI: 10.1128/AAC.49.7.2642-2647.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.

Authors:  M Souli; C B Wennersten; G M Eliopoulos
Journal:  Int J Antimicrob Agents       Date:  1998-04       Impact factor: 5.283

2.  Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.

Authors:  A Forrest; S Chodosh; M A Amantea; D A Collins; J J Schentag
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

3.  Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.

Authors:  A A Firsov; R G Vasilov; S N Vostrov; O V Kononenko; I Y Lubenko; S H Zinner
Journal:  J Antimicrob Chemother       Date:  1999-04       Impact factor: 5.790

4.  Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species.

Authors:  H M Siefert; A Domdey-Bette; K Henninger; F Hucke; C Kohlsdorfer; H H Stass
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

5.  Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.

Authors:  S N Vostrov; O V Kononenko; I Y Lubenko; S H Zinner; A A Firsov
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997).

Authors:  Ronald N. Jones; Matthew A.T. Croco; Michael A. Pfaller; Mondell L. Beach; Kari C. Kugler
Journal:  Clin Microbiol Infect       Date:  1999-09       Impact factor: 8.067

7.  Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.

Authors:  R Teng; S C Harris; D E Nix; J J Schentag; G Foulds; T E Liston
Journal:  J Antimicrob Chemother       Date:  1995-08       Impact factor: 5.790

8.  Pharmacokinetic considerations in quinolone therapy.

Authors:  C H Nightingale
Journal:  Pharmacotherapy       Date:  1993 Mar-Apr       Impact factor: 4.705

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

10.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  9 in total

1.  Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health.

Authors: 
Journal:  Thorax       Date:  2007-01       Impact factor: 9.139

2.  Antibiotic pharmacodynamics and bacterial resistance: usefulness of in vitro models.

Authors:  Stephen H Zinner; Alexander Firsov
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

3.  Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.

Authors:  O Murillo; M E Pachón; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

4.  Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.

Authors:  O Murillo; A Doménech; A Garcia; F Tubau; C Cabellos; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

5.  In Vitro Mechanistic Study of the Distribution of Lascufloxacin into Epithelial Lining Fluid.

Authors:  Kouhei Ohya; Junichi Takano; Shigeru Manita
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

6.  Moxifloxacin dosing in post-bariatric surgery patients.

Authors:  Pieter Colin; Douglas J Eleveld; Michel M R F Struys; Huybrecht T'Jollyn; Luc M Van Bortel; Johannes Ruige; Jan De Waele; Jan Van Bocxlaer; Koen Boussery
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

7.  Pandemic flu. Clinical management of patients with an influenza-like illness during an influenza pandemic.

Authors: 
Journal:  J Infect       Date:  2006-12       Impact factor: 6.072

8.  Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.

Authors:  Joseph S Bertino
Journal:  Clin Ophthalmol       Date:  2009-09-24

9.  Skin and skin structure infections: treatment with newer generation fluoroquinolones.

Authors:  Philip Giordano; Kurt Weber; Gail Gesin; Jason Kubert
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.